Voyager Therapeutics Stock (NASDAQ: VYGR)

Voyager Therapeutics (NASDAQ:VYGR) Stock, Quote.Headers.trade-ideas

Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Biotech

Earnings

Earnings Beats

News

Penny Stocks

Small Cap

Markets

Trading Ideas

General

ANIP

LGND

PBYI

VYGR

Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.

Puma Biotechnology&#39;s Q1 Earnings and Revenues Beat

pharma lab worker ai

Analyst Color

Equities

Health Care

Price Target

Initiation

Analyst Ratings

Movers

NBIX

SGMO

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term value.

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

Wall Street bull

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

Pre-Market Outlook

Tech

ETFs

AVGO

BBWI

BFLY

DUOL

ENPH

FIGS

IRWD

LPSN

MNST

NFLX

NVDA

PLCE

STER

TSLA

PowerShares DB US Dollar Index Bullish Fund

XMTR

Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&amp;P 500, and small caps.

Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics Inc

Selection of the development candidate triggered a&nbsp;$3 million&nbsp;milestone payment to Voyager, which the Company expects to receive in the&nbsp;fourth quarter&nbsp;of 2024.
Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.
Under the terms of the 2023 collaboration agreement, for each of the three undisclosed programs, Voyager is eligible to receive up to&nbsp;$175 million&nbsp;in potential development milestone payments plus substantial potential commercial milestone payments, as well as tiered high single-digit to mid-teens royalties on U.S. net sales and mid-single-digit to low double-digit royalties on ex-U.S. net sales. Neurocrine Biosciences will fund the development of each program.

Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment

Voyager Therapeutics Announces Novartis Licensing Novel Capsid From TRACER Platform For Use In Gene Therapy Targeting Undisclosed Rare Neurologic Disease​

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $30 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target

WIIM

Voyager Therapeutics shares are trading lower. The company reported Q2 financial results and Wedbush lowered its price target on the stock from $8 to $7.

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Neutral and lowers the price target from $8 to $7.

Wedbush Maintains Neutral on Voyager Therapeutics, Lowers Price Target to $7

Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.43) by 58.14 percent. The company reported quarterly sales of $29.578 million which beat the analyst consensus estimate of $9.461 million by 212.64 percent. This is a 509.48 percent increase over sales of $4.853 million the same period last year.

Voyager Therapeutics Q2 2024 GAAP EPS $(0.18) Beats $(0.43) Estimate, Sales $29.578M Beat $9.461M Estimate

In the preceding three months, 4 analysts have released ratings for Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target of $21.5, a high estimate of $30.00, and a low estimate of $8.00. A decline of 2.27% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1722430847_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Voyager Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Voyager Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Voyager Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Voyager Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Voyager Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VYGR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Voyager Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Voyager Therapeutics</h2>
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
<h3>A Deep Dive into Voyager Therapeutics's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Voyager Therapeutics faced challenges, resulting in a decline of approximately -87.03% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Voyager Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -58.05% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Voyager Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.76%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Voyager Therapeutics Stock

&nbsp;Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

Management

Voyager Therapeutics Taps Nathan Jorgensen of Vor Bio as CFO, Effective July 8

Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease

Oppenheimer analyst Jay Olson maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Outperform and maintains $18 price target.

Oppenheimer Maintains Outperform on Voyager Therapeutics, Maintains $18 Price Target

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Neutral and lowers the price target from $10 to $8.

Wedbush Maintains Neutral on Voyager Therapeutics, Lowers Price Target to $8

Guidance

Voyager Therapeutics Reports Cash Position Of Approximately $400M At Quarter-End, With Runway Into 2027

Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.45) by 55.56 percent. This is a 106.8 percent decrease over earnings of $2.94 per share from the same period last year. The company reported quarterly sales of $19.516 million which beat the analyst consensus estimate of $9.415 million by 107.29 percent. This is a 87.03 percent decrease over sales of $150.480 million the same period last year.

Voyager Therapeutics Q1 2024 GAAP EPS $(0.20) Beats $(0.45) Estimate, Sales $19.516M Beat $9.415M Estimate

<ul>
<li>Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding</li>
<li>Preclinical safety and efficacy demonstrated in Alzheimer&#39;s disease and ALS gene therapies; low IV doses provided broad CNS biodistribution and robust transduction of key cell types</li>
</ul>

Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbyi#NASDAQ">PBYI</a>) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.
The above-adjusted loss excludes the impact of stock-based compensation expense. Including the same, reported loss per share was 10 cents in the first quarter of 2024 against earnings of 3 cents reported in the year-ago quarter.
In the first quarter, total revenues were $43.8 million, which beat the Zacks Consensus Estimate of $42 million.
Revenues, however, decreased around 17% year over year. Total revenues comprised net product sales of Nerlynx (neratinib), Puma Biotechnology&#39;s only marketed drug in the United States, and royalty revenues. Nerlynx is indicated for treating early-stage HER2-positive breast cancer.
Shares of Puma Biotechnology have rallied 14.6% so far this year against the industry&#39;s 8.8% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/63/66104.jpg?v=510077615" /> 
Image Source: Zacks Investment Research
<h3>Quarter in Detail</h3>
Product revenues from Nerlynx were $40.3 million in the reported quarter, down 13.9% year over year, as sales were negatively impacted by inventory drawdown at specialty pharmacies and specialty distributors. However, Nerlynx&#39;s product sales were higher than the guidance range of $38-$40 million.
Product revenues also beat the Zacks Consensus Estimate of $38.6 million, as well as our model estimate of $38.5 million. Nerlynx revenues decreased 24.2% sequentially.
On the first-quarter conference call, management stated that overall demand for Nerlynx declined around 18% year over year and 8% sequentially. Nerlynx total prescriptions decreased 16% year over year and 3% sequentially in the first quarter. New prescriptions increased 27% sequentially but declined 15% year over year.
Royalty revenues were $3.5 million, down almost 41.7% from the year-ago quarter. Royalty revenues decreased 81.5% on a sequential basis due to the timing of shipments to PBYI&#39;s partner in China. Royalty revenues beat our model estimate of $2.9 million.
Puma Biotechnology did not record any license revenues in the first quarter.
Total operating costs (including stock-based compensation expense) in the quarter were $46.1 million, down 4.8% year over year.
Selling, general and administrative expenses (including stock-based compensation expense) were down 3.1% year over year to $21.8 million.
Research and development expenses (including stock-based compensation expense) were $13.6 million in the quarter, up 7.1% year over year.
Cash, cash equivalents and marketable securities were $107.2 million as of Mar 31, 2024, compared with $96 million as of Dec 31, 2023.
<h3>2024 Guidance</h3>
Puma Biotechnology expects Nerlynx&#39;s product sales to be in the range of $183-$190 million in 2024, unchanged from the previous guidance range. In the second quarter of 2024, Nerlynx product sales are expected in the band of $43-$45 million.
Royalty revenues are expected to be in the $30-$33 million range in 2024, also unchanged from the previous guidance range. In the second quarter of 2024, royal revenues are expected in the band of $2.5-$3.0 million.
The company expects license revenues to be in the range of $1-$2 million in 2024.
Net income is expected to be in the range of $12-$15 million in 2024. PBYI expects to report net loss in the range of $6-$9 million in the second quarter of 2024.
<h3>Pipeline Update</h3>
Puma Biotechnology in-licensed the global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan&#39;s Takeda in 2022.
In March 2024, the FDA notified the company that its investigational new drug application has been reviewed and that it can proceed with the clinical development of alisertib for the treatment of patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer in the phase II ALISCA-Breast1 trial study. The study is likely to be initiated in the fourth quarter of 2024.
PBYI is already conducting ALISCA-Lung1, a phase II study (PUMA-ALI-4201) evaluating alisertib as monotherapy for the treatment of patients with extensive stage small cell lung cancer. Interim data from the study is expected in the fourth quarter of 2024.
Meanwhile, alisertib is also being studied in combination with Tagrisso (osimertinib) in patients with metastatic EGFR-mutant non-small cell lung cancer who have developed Tagrisso resistance. Updated data from this study is expected later in the second quarter of 2024.
<div class="chart_embed">
<h3>Puma Biotechnology, Inc. Price, Consensus and EPS Surprise</h3>
<a href="https://www.zacks.com/stock/chart/PBYI/price-consensus-eps-surprise-chart?icid=chart-PBYI-price-consensus-eps-surprise-chart"><img alt="Puma Biotechnology, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/bf/1714740085.png" style="height:265px; width:574px" title="" /> </a>
Puma Biotechnology, Inc. price-consensus-eps-surprise-chart | Puma Biotechnology, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Puma Biotechnology currently has a Zacks Rank #3 (Hold).
Some top-ranked stocks in the healthcare sector are Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>), Ligand Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgnd#NASDAQ">LGND</a>) and ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Voyager Therapeutics&#39; 2024 loss per share have narrowed from $1.89 to $1.64. Year to date, shares of VYGR have increased 1.1%.
VYGR&#39;s earnings beat estimates in three of the trailing four quarters and missed the same once, the average surprise being 545.93%.
In the past 60 days, estimates for Ligand&#39;s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have risen 1.3%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have improved from $4.25 to $4.44. Year to date, shares of ANIP have jumped 21.7%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.
<a href="https://www.zacks.com/stock/news/2268089/puma-biotechnology-s-pbyi-q1-earnings-and-revenues-beat?cid=CS-BENZ-FT-analyst_blog|earnings_article-2268089">To read this article on Zacks.com click here.</a>

Puma Biotechnology's Q1 Earnings and Revenues Beat

Events

Voyager Therapeutics To Present Translational Data For IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials At ASGCT 27th Annual Meeting

Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024

Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics (VYGR – Research Report), Amg...

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Amgen (AMGN) and ACADIA Pharmaceuticals (ACAD)

Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), retaining the price target o...

Buy Rating Affirmed for Voyager Therapeutics on Robust Pipeline and Strong Financial Position

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating on August 15. Patrick Trucchio has ...

Buy Rating Affirmed: Voyager Therapeutics' Advancements and Revenue Potential in CNS Gene Therapy

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects

The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and substantial recent earnings surprises.

3 High-Growth Stocks Poised To Double By Next Year

Novartis licenses gene therapy component from Voyager

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report). The company's ...

Truist Financial Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)

Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Voyager Therapeutics (VYGR – Research Report). The associated price targe...

Voyager Therapeutics: A Strong Buy on Gene Therapy Prospects and Strategic Novartis Partnership

The U.S. Federal Reserve beat inflation far sooner than expected. Now Jerome Powell is on track to cut rates and ease in for a "soft" landing sooner than expected.

Get "Picky" With Stocks For September Profits

AAPL

ACAD

AMGN

AMZN

GOOGL

MSFT

NVSEF

Press Releases

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Financing

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Voyager Therapeutics

Voyager Therapeutics (VYGR) Forecast

Voyager Therapeutics (NASDAQ:VYGR) Stock, Quote.Headers.trade-ideas